Teva Pharmaceutical Industries Ltd., commonly known as Teva, is a leading global player in the pharmaceutical industry, headquartered in Israel (IL). Founded in 1901, Teva has established itself as a prominent manufacturer of generic pharmaceutical products, with a diverse portfolio that spans various therapeutic areas, including pain management, respiratory, and central nervous system disorders. With a strong presence in North America, Europe, and other key markets, Teva is renowned for its commitment to quality and accessibility in healthcare. The company’s extensive range of generic medications is distinguished by its rigorous adherence to regulatory standards and innovative approaches to drug formulation. Teva's market position is bolstered by its status as one of the largest generic drug manufacturers worldwide, achieving significant milestones in both product development and market expansion.
How does Teva Pharmaceutical Industries Ltd., Portfolio Of Generic Pharmaceutical Products's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Teva Pharmaceutical Industries Ltd., Portfolio Of Generic Pharmaceutical Products's score of 21 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Teva Pharmaceutical Industries Ltd., Portfolio Of Generic Pharmaceutical Products, headquartered in Israel (IL), currently does not have specific carbon emissions data available for the most recent year. The company is part of a corporate family that includes AbbVie Inc., from which it inherits climate-related commitments and initiatives. As a merged entity, Teva's climate commitments are influenced by AbbVie Inc.'s sustainability strategies. However, no specific reduction targets or achievements have been documented for Teva at this time. The absence of emissions data and defined reduction initiatives suggests that the company may still be in the process of establishing its own climate action framework. Teva's climate commitments are likely aligned with industry standards, but without concrete data or targets, it is challenging to assess their current impact on carbon emissions. The company’s future climate strategies may evolve as it continues to integrate sustainability practices from its parent organization.
Access structured emissions data, company-specific emission factors, and source documents
| 2005 | 2010 | 2011 | 2012 | 2015 | 2016 | 2017 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 28,218,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 
| Scope 2 | 59,189,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Teva Pharmaceutical Industries Ltd., Portfolio Of Generic Pharmaceutical Products has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.